Veterinary medicine - ANMV

The provisions relating to the advertising of veterinary medicinal products are regulated by the European Regulation 2019/6 and supplemented, in France, by other obligations added in the Public Health Code (PHC). The main French provisions are as follows: Advertising for veterinary medicinal products may only be carried out by the marketing authorisation holder (MAH) of the medicinal products concerned by the advertisement or by the representative declared by the MAH in accordance with the provisions of Article L.5142-1.5 - I of the PHC. Only authorised veterinary medicinal products (marketing authorisation or parallel trade) or registered in France may be advertised in any form. Advertising in favour of veterinary medicinal products shall be authorised to physical person or legal entity authorised to issue them by Articles L. 5143-2 and L. 5143-6 of the PHC only for those whom they are authorised to prescribe or to issue. Public advertising is only possible for veterinary medicinal products not subject to veterinary prescription. Where medicinal products are being promoted to persons qualified to prescribe or supply them in accordance with the Regulation, no gifts, pecuniary advantages or benefit in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of prescription or supply of medicinal products. All advertising materials must be submitted to Anses-ANMV for declaration or authorisation, at least 2 months prior to their dissemination (transmission of the projects to publicite-anmv@anses.fr ).

Joint interview with Jean-Pierre Orand, Director of the French Agency for Veterinary Medicinal Products (ANMV) within ANSES, and Caroline Semaille, Deputy Director General in charge of Operations at the French Health Products Safety Agency (ANSM).

This report takes stock of the activities of the French agency for veterinary medicinal products in 2021 with the highlights of the past year. It proposes a review of all the Agency’s actions in the field of veterinary medicinal products and details in particular the changes brought about by the entry into force of the Regulation on veterinary medicinal products. View the 2021 report for veterinary medicinal products (PDF)

Veterinary medicine quality is vital and must be ensured throughout the pharmaceutical chain, from design until use. Each participant in the chain has an influence on one or more parameters and needs to take precautions to guarantee and maintain veterinary medicine quality. During the summer, especially in cases of high heat, the storage of veterinary medicinal products may be affected; beyond 40 °C, there are risks of irreversible degradation (quality, effectiveness) or even toxicity (formation of degradation products).

The conference was organised in several sessions. In the first session, the context of the use of plants in veterinary medicine in the European Union was presented and the various stakeholders (farmers, veterinarians and pharmaceutical industries) were able to share their expectations and problems with the use of veterinary herbal medicines. Secondly, two experts from the Human Committee on Herbal Medicinal Products presented a feedback on the problems encountered in the authorisation of herbal medicinal products for human use compared to conventional chemical medicinal products. Then, the Anses-ANMV gave a feedback on the work carried out by France, in particular on the referral 2014-SA-0083 . Finally, these sessions continued with the presentation of the perspectives at European level by the EMA and the European Commission and the sharing of the views of the participants. Conference overview